Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Launches "One Less" Gardasil DTC Ads Targeting Teens

This article was originally published in The Pink Sheet Daily

Executive Summary

Campaign for the cervical cancer vaccine includes print, broadcast and online ads.

You may also be interested in...



Gardasil Gains Blockbuster Status In Its First Year On The Market

Merck’s HPV vaccine generated $1.1 billion in sales year-to-date, firm reports during third quarter earnings call.

Gardasil Gains Blockbuster Status In Its First Year On The Market

Merck’s HPV vaccine generated $1.1 billion in sales year-to-date, firm reports during third quarter earnings call.

Public Education On HPV Needed, Studies Find

As Gardasil's launch ramps up, one survey finds limited awareness of HPV, while another suggests that discussing the product in the context of sexual transmitted disease could reduce interest in vaccination.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel